Dicyclomine Tablet Dosage
For adults with irritable bowel syndrome, start dicyclomine at 20 mg four times daily (80 mg/day), then increase to 40 mg four times daily (160 mg/day) if tolerated, which is the FDA-approved therapeutic dose. 1
Adult Dosing
The standard dosing regimen is:
- Initial dose: 20 mg orally four times daily
- Target therapeutic dose: 40 mg orally four times daily (160 mg/day total)
- Maximum dose: Do not exceed 160 mg/day
In clinical trials, 82% of patients treated with dicyclomine 160 mg daily (40 mg four times daily) showed favorable response compared to 55% with placebo 1. The 40 mg four times daily regimen is the evidence-based therapeutic dose.
Dose adjustment for side effects: If anticholinergic side effects occur at 160 mg/day, reduce to an average of 90 mg/day in divided doses. In clinical trials, 46% of patients with side effects required this reduction but maintained therapeutic benefit 1.
Elderly Patients
No specific FDA dosage adjustment is provided based on age alone 1. However, use caution as elderly patients may have:
- Decreased renal function (requiring consideration of lower doses)
- Increased sensitivity to anticholinergic effects
- Higher risk of confusion, urinary retention, and constipation
Start at the lower end of the dosing range (20 mg four times daily) and monitor closely for adverse effects before escalating.
Hepatic Impairment
No specific dosage adjustments are provided in the FDA labeling for hepatic impairment 1. Since dicyclomine undergoes hepatic metabolism, use with caution in patients with liver disease and monitor for increased anticholinergic effects.
Renal Impairment
No specific dosage adjustments are provided in the FDA labeling for renal impairment 1. However, since 79.5% of dicyclomine is eliminated via urine 1, consider dose reduction in severe renal impairment and monitor for accumulation and increased side effects.
Pediatric Dosing (Ages 5-17 Years)
Dicyclomine is contraindicated in infants less than 6 months of age 1. For children aged 6 months to 17 years, the FDA labeling does not provide specific pediatric dosing recommendations for the tablet formulation 1.
The available evidence only addresses:
- Infants with colic (3 mg/kg/day was studied but is NOT recommended due to safety concerns) 2
- No established dosing for children 5-17 years in the FDA labeling
Use in children should be approached with extreme caution and only when benefits clearly outweigh risks, as pediatric safety and efficacy have not been established.
Important Clinical Considerations
Common anticholinergic side effects (occurred in 61% of patients at 160 mg/day) 1:
- Dry mouth (33%)
- Dizziness (29%)
- Blurred vision (27%)
- Nausea (14%)
Contraindications 1:
- Obstructive uropathy or GI obstruction
- Severe ulcerative colitis
- Glaucoma
- Myasthenia gravis
- Infants <6 months
- Nursing mothers
Critical warning: Never administer dicyclomine intravenously—this can cause thrombosis 3. The approved routes are oral and intramuscular only.